A Phase 4 interventional study of Anti-VEGF agents and tissue plasminogen activator (rtPA) in Polypoidal Choroidal Vasculopathy (PCV) and Submacular Hemorrhage, sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine. Not yet recruiting. Open to participants aged 45 Years to 95 Years. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this randomized clinical trial is to determine whether adding recombinant tissue plasminogen activator (rtPA), a clot-dissolving medicine, to gas injection and anti-VEGF treatment improves outcomes in people with submacular hemorrhage (SMH) caused by polypoidal choroidal vasculopathy (PCV).
The main questions it aims to answer are:
Researchers will compare two pneumatic displacement (PD) strategies: anti-VEGF treatment plus C3F8 gas and rtPA (triple PD) and anti-VEGF treatment plus C3F8 gas without rtPA (dual PD). This comparison will assess the additional benefits and risks of rtPA. The study will enroll 80 participants at a single center. Participants will be randomly assigned to one of the two groups, with an equal chance of receiving either treatment.
The primary outcome is complete SMH displacement at 1 week, defined as no remaining blood beneath the fovea on optical coherence tomography (OCT), a scan that produces detailed images of the retina. Secondary outcomes include changes in best-corrected vision at 6 months, vitreous hemorrhage within 1 month, retinal detachment and other serious complications during follow-up, and the number of anti-VEGF injections over 6 months.
Participants will:
55 studies on the registry are indexed under Polypoidal Choroidal Vasculopathy; 7 are open to participants now.
This study's planned enrollment of 80 is above the median of 50 across 40 interventional studies indexed under Polypoidal Choroidal Vasculopathy.
Browse Polypoidal Choroidal Vasculopathy studies →Second Affiliated Hospital, Zhejiang University, School of Medicine is the lead sponsor of 106 studies on the registry; 72 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intravitreal injection of an anti-VEGF agent, intravitreal injection of rtPA (off-label), and intravitreal gas injection for pneumatic displacement.
Drug: Anti-VEGF agents · Drug: tissue plasminogen activator (rtPA) · Procedure: Pneumatic displacement with intravitreal gas
Intravitreal injection of an anti-VEGF agent and intravitreal gas injection for pneumatic displacement.
Drug: Anti-VEGF agents · Procedure: Pneumatic displacement with intravitreal gas
Intravitreal injection of an anti-VEGF agent (specific agent and dose per study protocol) as part of pneumatic displacement treatment for PCV-related submacular hemorrhage.
Intravitreal injection of rtPA as an off-label adjunct to pneumatic displacement, administered only in the triple PD arm at the dose specified in the study protocol, to promote clot liquefaction and facilitate submacular hemorrhage displacement.
Intravitreal gas injection (gas type and volume per study protocol) followed by post-injection positioning, performed to displace submacular hemorrhage away from the fovea. This procedure is used in both study arms.
Rate of complete SMH displacement at 1 week after the procedure.
No residual submacular hemorrhage in the foveal area on OCT.
Time frame: 1 week after procedure
Incidence of vitreous hemorrhage (VH) and proportion undergoing vitrectomy due to VH within 1 month after the procedure
Incidence of vitreous hemorrhage within 1 month after the procedure and the proportion of participants requiring pars plana vitrectomy (PPV) because of vitreous hemorrhage.
Time frame: Within 1 month after the procedure
Incidence of severe postoperative complications, including retinal detachment
Incidence of severe complications after the procedure, including retinal detachment.
Time frame: Within 3 months after the procedure
Change in best-corrected visual acuity (BCVA) at 6 months
Change from baseline in best-corrected visual acuity (BCVA) at 6 months after the procedure, to assess visual prognosis.
Time frame: At 6 months after the procedure
Macular anatomical outcomes at 6 months
Recovery of macular anatomy at 6 months after the procedure, including central macular thickness (CMT) , pigment epithelium detachment (PED) volume, and SMH absorption/resolution, to assess anatomical prognosis.
Time frame: At 6 months after the procedure
Number of anti-VEGF injections within 6 months after the procedure
Total number of anti-VEGF injections administered within 6 months after the procedure.
Time frame: Within 6 months after the procedure
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jan 2027; primary completion for Jun 2029, 29 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Polypoidal Choroidal Vasculopathy →
Second Affiliated Hospital, Zhejiang University, School of Medicine →